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Treatment of mesangial cells with recombinant human interleukin 18 (IL-1S) or recombinant human tumor necrosis factor a (TNFa) dose-depen- 
dently increased cGMP formation. Both IL-l/3 and TNFa-stimulated formation of cGMP occurred after a initial lag period of 4 to 8 hours. Treat- 
ment of cells with actinomycin D, cycloheximide or dexamethason completely abolished cytokine-induced cGMP formation. Furthermore, the 
guanylate cyclase inhibitor Methylene blue completely blocked IL &!I- and TNFa-stimulated cGMP generation. NO-mono-methyl-L-arginine atten- 
uated IL-l/?- and TNFa-induced cGMP production, an effect that was reversed by L-arginine. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
IL-l and TNFa( are polypeptide hormones produced 
mainly by macrophages and play a central role in the 
pathogenesis of acute glomerular injury and nephritis 
[l]. Proliferation of mesangial cells is a hallmark of 
progressive glomerular disease and IL-l and TNFcv syn- 
thesized by mesangial cells may serve to perpetuate pro- 
liferation in an autocrine manner [2,3]. Furthermore, 
IL-1 stimulates the release of a specific type IV col- 
lagenase [4] and both cytokines, IL-1 and TNF~Y, 
enhance the synthesis and release of phospholipase AZ 
and prostaglandins from mesangial cells [5]. 
2.1. Chemicals 
Recombinant humau IL-W (> 10’ W/ml) was prepared by the 
Biotechnology Department of Ciba-Geigy Ltd, Basel, Switzerland; 
recombinant human TNFa! (> 10’ U/ml) was obtained from Boehr- 
inger Mannheim; FRG, Methylene blue, L-arginine, No-mono- 
methyl-L-arginine acetate (NMMA), cycle-heximide, actinomycin D 
and dexamethason were obtained from Sigma, St. Louis, MO; all cell 
culture nutrients were from Boehringer Mannheim, FRO; all other 
chemicals were from Merck, Darmstadt, FRG. 
2.2. Cel( culture 
The signalling pathways triggered by IL-1 and TNFa 
are far from clear, for there are a number of reports, 
each suggesting adifferent second messenger system. In 
mesangial cells IL-1 and TNFa have no direct effect on 
phosphoinositide hydrolysis and Ca’+ mobilization 
([6], J. Pfeilschifter and M. Ochsner, unpublished 
results) or on CAMP generation formation [7,8]. 
Recently, Kester and colleagues reported that IL-l ac- 
tivates a phosphatidylethanolamine-degrading phos- 
pholipase C in mesangial cells [6]. In the present study, 
we have investigated the effects of IL-l,& and TNFLv on 
cGMP formation in mesangial cells. The present data 
suggest that the NO-producing L-arginine pathway is 
activated in mesangial cells follows a~i~stration of 
IL-l@ or TNFiv with a subsequent increase in cellular 
cGMP levels. 
Rat renal mesangial cells were cultivated as described previously 
[9]. The cells were grown in RPM1 1640 supplemented with 20% fetal 
calf serum, penicillin (100 U/ml), streptomycin (100 ag/ml) and 
bovine insulin at 0.66 U/ml (Sigma). Mesangial cells were characteriz- 
ed mo~hologi~~y by phase contrast microscopy, positive staining 
for the intermediate filaments desmin and vlmentin, which is con- 
sidered to be specific for myogenic ells [lo], negative staining for fac- 
tor VIII related antigen and cytokeratin, excluding endothelial and 
epithelial contaminations, respectively. 
2.3. Incubation of cells and cGMP determination 
Confluent mesangial cells in 35 mm diameter dishes were prein- 
cubated with IL-la or TNFcv together with the different inhibitors for 
the indicated time periods. Thereafter, the medium was removed and 
the cells were rinsed twice and incubated for an additional 10 min, 
either in the presence or absence of the phosphodiesterase inhibitor 
3-isobutyi I-methylxan~ine (IBMX) (0.5 mM). The reaction was ter- 
minated by aspiration of the medium and addition of 1 ml ice-cold 
5% (w/v} trichloroacetic acid. For extraction of cGMP the dishes 
were put on ice for 1 h. The trichloroacetic acid was then removed by 
3 extractions with 10 x volume of water-saturated d&ethyl ether, and 
cGMP was determined by radioimmunoassay (New England 
Nuclear). 
Correspondence address: J. Pfeilschifter, Ciba-Geigy Ltd, R-1056. 
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3. RESULTS 
Abbreviations: IL-l, interleukin 1; TNF, tumor necrosis factor; 
IBMX, 3-isobutyl 1-methylxanthine; NMMA, No-monomethyl-L- 
arginine 
Short-term incubations of mesangial cells with IL-l,& 
or TNFa for 20,40, and 60 min did not increase cellular 
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cGMP levels, irrespective of whether phosphodiesterase 
was blocked by IBMX or not (data not shown). In a 
next step, cells were preincubated with IL-l@ or TNFcv 
for 24 h and cGMP formation was determined. Basal 
levels of cGMP in control cells were 0.34 f 0.04 pmol/ 
mg of protein and treatment with IL-lp (I nM) or 
TNFar (1 nM) increased these values to 5.3 + 0.4 and 
l.OzizO.3 pmollmg of protein, respectively (values are 
means f SD, n = 4). In the presence of IBMX (0.5 mM) 
for a 10 min period after cytokine treatment, the effects 
of both IL-l,& and TNFa! were greatly enhanced (Table 
Table I 
Dose-dependence of IL-la- and TN&-stimulated cGMP formation 
in mesangial cells 
Addition cGMP (pmol/mg of protein) 
Control 1.8 + 0.2 
IL-h7 1 pM 2.3 f 0.4 
10 pM 5.8 f 0.7 
100 pM 52.0 + 9.8 
1 nM 434 f 160 
10 nM 392 f 32 
TNFa 1 pM 2.0 f 0.4 
10 pM 9.4 * 2.2 
100 pM 21.0 f 1.2 
1 nM 41.2 f 3.7 
10 nM 169 4 28 
Mesangial cells were preincubated for 24 h with the indicated concen- 
trations of IL-l@ or TNFcu. Thereafter, the medium was removed and 
the cells were incubated for an additional 10 min in the presence of 
IBMX (0.5 mM) and cGMP was determined as described in section 2. 
Results are means k SD for 4 experiments 
Table II 
Effect of different compounds on IL-l,& and TNFru-stimulated 




IL-la + NMMA (1OpM) 
IL-l/9 + NMMA (10pM) + 
cGMP (pmol/mg of protein) 
6.7 f 1.2 
275 f 63 
136 f 23 
L-arginine (2 mlvl) 235 -+ 24 
11-18 + Methylene blue (50 ,uM) 0.4 f 0.3 
IL-l@ + actinomycin D (10 PM) 6.8 f 0.6 
IL-18 + cyclohe~de f 10 pM) 10.1 f 0.2 
IL-l,& + dexamethason (1 FM) 12.5 f 2.3 
TNF 37.8 T 7.8 
TNF -I- NMMA (lOgM) 23.9 f 2.7 
TNF + NMMA(lOpM) + 
L-arginine (2 mM) 35.1 f 3.1 
TNF + Methylene blue (50 FM) 0.3 f 0.1 
TNF + actinomycin D (10rM) 1.5 * 0.4 
TNF + cycloheximide (10 ,uM) 3.1 f 0.3 
TNF + dexamethason (1 ,uM) 4.0 f 1.0 
Mesa&al cells were preincubated for 24 h with IL-W (1 nM) or 
TNFa, (1 nM) together with the indicated drugs. Thereafter, the 
medium was removed and the cells were incubated for an additional 
10 min in the presence of IBMX (0.5 mM) and cGMP was determined 
as described in Section 2. Results are means f SD for 4 experiments 
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Fig. 1. Time-course of IL-l& and TNFar-stimulated cGMP formation 
in mesangial cells. Mesangial cells were preincubated with IL-lb (1 
nM) or TNFa( (1 nM) for 24 h. Thereafter, the medium was removed 
and the cells were incubated for an addition 10 min in the presence of 
IBMX (0.5 mM) and cGMP was determined as described in section 2. 
Results are means f SD for 4 experiments. 
1). This indicates that the effect of II-lfi and TNFtv on 
cGMP were due to stimulation of guanylate cyclase 
rather than to i~bition of cGMP degradation by 
phosphodiesterase. Further evidence for this suggestion 
is provided by the complete inhibition of cytokine- 
induced cGMP formation by the guanylate cyclase in- 
hibitor MethyIene blue (Table II). As shown in Table I 
IL-l,& and TNFQ-stimulated formation of cGMP was 
dose-dependent with a significant stimulation occurring 
at 10 pM. The induction of cGMP formation by both 
cytokines requires a lag time of 4 to 8 h as shown in 
Fig. 1. Co-incubation with actinomycin D (10 PM), 
cycloheximide (10yM) or dexamethasone (1 /cM) com- 
pletely suppressed IL-lfl- or AFT-stimulated cGMP 
formation (Table II), indicting that an increase in both 
transcription and translation is involved. Co-incubation 
with NMMA (10 FM) attenuated IL-l& and TNFtu- 
stimulated cGMP formation as shown in Table II. L- 
arginine (2 mM) added together with NMMA 
counteracted the effect of NMMA (Table II), thus sug- 
gesting that an NO-like substance is involved in 
cytokine-induced cGMP formation in mesangial cells. 
4. DISCUSSION 
Mesangial cells are a major determinant in the regula- 
tion of the glomerular filtration rate 1111. Mor- 
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phologically, mesangial cells resemble vascular smooth 
muscle cells and are able to contract upon stimulation 
by vasoactive hormones like angiotensin II (see [12,13] 
for review). The interaction of infiltrating monocytes 
and intrinsic mesangial cells plays an important role in 
the pathogenesis of certain forms of immune-mediated 
glomerulonephritis [11. The release of IL-1 or TNFcv by 
infiltrating monocytes promotes mesangial cell pro- 
liferation [2,3], secretion of phospholipase A2 and pro- 
stanoids [5], as well as secretion of a neutral proteinase 
activity [4]. These events may contribute to the mor- 
phological changes observed in progressive glomerular 
diseases. 
To our knowledge, this is the first report demon- 
strating that IL-l,& and TNFcv potently increase cGMP 
levels in mesangial cells. The lag period of 4 to 8 h, as 
well as the inhibitory effects of actinomycin D, cyclo- 
heximide and dexamethason indicate that both cyto- 
kines induce the synthesis of a protein that may be 
responsible for the chronic stimulation of guanylate 
cyclase activity in mesangial cells. The inhibitory effect 
of NMMA, a competitive inhibitor of nitric oxide syn- 
thase and its reversal by L-arginine suggest hat IL-lfl 
and TNFa stimulate the synthesis of a NO-like inter- 
mediate in mesangial cells which increases cGMP by ac- 
tivating soluble guanylate cyclase. This suggestion is 
further strengthened by the complete inhibition of 
cytokine-evoked cGMP generation by Methylene blue, 
an inhibitor of soluble guanylate cyclase. Lipopolysac- 
charide preparations which are well known stimulators 
of cytokine production [14] have been shown to stimu- 
late cGMP formation in rat liver [ 151 and spleen cells 
[ 161. As in mesangial cells, a lag period of 2 h was re- 
quired and cGMP accumulation was blocked by ac- 
tinomycin D and cycloheximide. Furthermore, lipoly- 
saccharide- and interferon y-stimulated murine macro- 
phages secrete NO [ 171. 
Elevations of mesangial cell cGMP levels cause relax- 
ation and result in an increased glomerular filtration 
rate [18]. However, it has been observed that the af- 
ferent arteriole and glomeruli are contracted in en- 
dotoxemia [19] and these events are accompanied by a 
fall in glomerular filtration rate [20]. Circulating pro- 
ducts of Gram negative bacteria are trigger substances 
that initiate these conditions in endotoxemia by 
stimulating the release of cytokines such as IL-l or TNF 
1141. A possible explanation for these contradictory 
results may be that IL-l and TNF also modulate other 
signalling pathways that are involved in the regulation 
of the contractile state of mesangial cells such as 
phosphoinositide turnover and adenylate cyclase activi- 
ty (Pfeilschifter and Schwarzenbach, unpublished 
results). The cross-communication between these 
signalling cascades will determine the final outcome in 
the cells and thus influence the functional parameter of 
increased or decreased cell contraction. Further ex- 
periments will be necessary to investigate the impor- 
tance of cytokine-induced NO formation in mesangial 
cells for the fall in glomerular filtration rate with subse- 
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